Aim: The Lupus Low Disease Activity State (LLDAS) is a potential treat to target goal in systemic lupus erythematosus (SLE). SLE patients in LLDAS for more than half of the observation time have about a 50% lower risk of new organ damage and have reduced mortality. We identified predictors of being in LLDAS !50% of the observation time. Methods: A total of 2228 SLE patients who had at least three clinical visits were included. Percentage of time in LLDAS was calculated based on the proportion of days under observation. LLDAS-50 was defined as being in LLDAS for !50% of the observation time. We used the stepwise selection procedure in logistic regression to identify predictors of LLDAS-50. Results: A total of 1169 (52.5%) SLE patients, but only 37.6% of African Americans, achieved LLDAS-50. In the multivariable model, African American ethnicity, hypocomplementemia, serositis, renal activity, arthritis, anti-RNP, anti-dsDNA, vasculitis, malar rash, discoid rash, thrombocytopenia, and immunosuppressive use were negative predictors of LLDAS-50. Older age at diagnosis, longer disease duration, higher education level, and greater percentage of time taking hydroxychloroquine remained positive predictors of LLDAS-50. Conclusion: In this large cohort, only 52.5% achieved LLDAS-50. This proportion was even less in African Americans. A higher percentage of time taking hydroxychloroquine was a modifiable positive predictor of LLDAS-50. Anti-RNP, anti-dsDNA, and low complement were negatively associated with LLDAS-50. Our findings further emphasize the importance of inclusion of African Americans in clinical trials and hydroxychloroquine adherence in both clinical practice and clinical trials. Lupus (2019) 28, 1648-1655.
Introduction
The clinical course of systemic lupus erythematosus (SLE) is highly variable among individuals and over time. 1 Both chronic disease activity and flares are associated with long-term organ damage and mortality. 2 Despite recent improvements in the management of SLE, patients with SLE still have a high risk of morbidity and mortality. 3 Achieving sustained remission is the ultimate goal of management of SLE, but it is rare. 4 Recently, a new potential treat to target goal, the Lupus Low Disease Activity State (LLDAS), was developed and validated by the Asia Pacific Lupus Collaboration. 5 LLDAS combines both low SLE activity and a low prednisone dose ( 7.5 mg/day). An increasing number of studies have applied LLDAS and found that LLDAS is an achievable target state and associated with a lower risk of new damage accrual [5] [6] [7] [8] [9] and better health-related quality of life. 10 LLDAS has been found as a discriminatory endpoint in post hoc analyses of successful clinical trials 11, 12 and in a prospective clinical trial. 13 Although there is no minimal duration requirement to fulfill the definition of LLDAS, as one might expect, greater percentage of time in LLDAS [7] [8] [9] and longer consequent duration of LLDAS 6 result in a better protective effect against organ damage. Furthermore, over 50% of time in LLDAS was associated with reduced mortality. 14 A few studies have analyzed the predictors of duration of time in LLDAS. Tani et al. reported that 36.5% of their 115 Italian SLE patients achieved LLDAS for at least five years. Higher SLE disease activity index (SLEDAI) at baseline and joint and skin involvement were found as negative predictors of five consecutive years in LLDAS. 9 Zen et al. found that 75.4% of their 293 Caucasian SLE patients were in LLDAS for at least two consecutive years. Higher SLE disease activity index 2000 (SLEDAI-2K), physician global assessment (PGA) score >1, skin involvement, methotrexate or cyclosporin treatment, and higher cumulative prednisone dose at baseline, as well as serositis, vasculitis, joint involvement and treatment with immunosuppressive drugs during the disease course, were found as negative predictors of two consecutive years in LLDAS. 6 Although over 50% of time in LLDAS (''LLDAS-50'') is associated with both reduced damage and mortality, 5, 14 studies of predictors of LLDAS-50 are lacking. Defining predictors of LLDAS-50 would be useful for stratification in clinical trials and for disease management. In this study, we addressed predictors of being in LLDAS !50% of the observation time in a large SLE cohort with both Caucasian and African American representation.
Methods
The Hopkins Lupus Cohort is a prospective longitudinal single-center cohort of SLE patients ongoing since 1987. It was approved on an annual basis by the Johns Hopkins University School of Medicine Institutional Review Board. All patients gave written informed consent to participate. Visits were scheduled quarterly by protocol. Patients were seen by one rheumatologist (MP). A total of 2228 SLE patients diagnosed according to the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria 15 or the revised classification criteria as defined by the American College of Rheumatology (ACR) 16 and as updated in 1997 17 and with at least three clinical visits were included in the analyses. At each clinic visit, the physician global disease activity on a 0-3 visual analog scale (PGA), 18 the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLEDAI (SELENA-SLEDAI), 19, 20 SLICC/ACR Damage Index (SDI), 21 relevant serologies (anti-dsDNA, complement), and treatment were recorded.
In this study, we applied LLDAS 5 to the Hopkins Lupus Cohort. LLDAS was defined as a SELENA-SLEDAI score of 4 with no scores for the renal, central nervous system, cardiopulmonary, vasculitis, fever, hemolytic anemia or gastrointestinal activity, no increase in any SELENA-SLEDAI component since the previous visit, a PGA of 1, and a prednisone dose of 7.5 mg/day. Immunosuppressants and hydroxychloroquine (HCQ) treatment were allowed in the LLDAS definition.
Using the information collected, we applied the aforementioned definition of LLDAS to determine whether LLDAS was achieved at each visit for each patient. To identify the number of days in LLDAS between any two clinical visits, if a patient was in LLDAS at current visit, days of LLDAS were calculated as days from current visit to next visit. To calculate the percentage of time in LLDAS, the patient's total number of days in LLDAS was divided by the total number of days of follow-up in the cohort. Follow-up times that occurred after a gap of more than seven months between clinic visits were excluded. LLDAS-50 was defined as being in LLDAS for at least 50% of the observation time.
Patients were then classified into groups based on whether they had achieved LLDAS-50 or not.
Logistic regression was used to identify patient characteristics that were associated with LLDAS-50. We evaluated the relationship between each variable and LLDAS-50 one at a time. Those identified as possible factors from the univariate analyses (p < 0.1) were further analyzed. A multivariable logistic regression model in a backward stepwise elimination manner was used to determine independent predictors of LLDAS-50. Hosmer-Lemeshow goodness of fit statistics were used to assess the model fit. and 97% antinuclear antibodies positivity based on the revised ACR classification criteria. Additional SLICC classification criteria included 21% direct Coombs test, 56% low C3, 48% low C4, and 17% low CH50. Mean follow-up in the cohort was 8.9 AE 7.5 years. Mean SLE duration at the last visit was 14 AE 9.6 years. Table 1 outlines the patient characteristics according to percentage of time in LLDAS, <50% versus !50%. Overall, 1169 (52.5%) patients, but only 37.6% African Americans, achieved LLDAS-50. Patients who were older at diagnosis, more educated, were Caucasian, had private insurance, had longer disease duration, a higher percentage of time taking HCQ, and accrued less damage during follow-up were more likely to have achieved LLDAS-50. The likelihood of LLDAS-50 was similar by gender, smoking history, anticardiolipin antibody and lupus anticoagulant (by dilute Russell's viper venom time test with confirmatory testing) positivity. The proportion of LLDAS-50 was lower in patients with a higher percentage of time taking an immunosuppressant drug, low C3, low C4, anti-Sm, anti-RNP, and anti-dsDNA positivity. Table 2 details the clinical manifestations. Patients with a history of mucosal ulcer and livedoid rash were more likely to have achieved LLDAS-50. The likelihood of LLDAS-50 or not was similar in patients with a history of photosensitive rash, Raynaud's, subacute cutaneous lupus erythematosus, bullous lupus, and panniculitis. Patients with a history of other clinical variables, including malar rash, discoid rash, alopecia, vasculitis, leg ulcers, arthritis, myositis, serositis, and hematological and renal manifestations, were less likely to have achieved LLDAS-50. Table 3 shows the characteristics of patients that were associated with LLDAS-50 based on the multivariable logistic regression model. In the multivariable model, African American ethnicity, history of anti-RNP, anti-dsDNA, low complement, serositis, vasculitis, renal activity, arthritis, malar rash, discoid rash, and thrombocytopenia, and percentage of time taking an immunosuppressant drug remained negative predictors. Older age at diagnosis, longer disease duration, higher education level, and higher percentage of time taking HCQ remained positive predictors of achieving LLDAS-50. Other covariates were not significant predictors of LLDAS-50, but included in the selection process were anti-Sm, photosensitive rash, mouth ulcers, alopecia, leg ulcers, livedo, myositis, Coombs positivity, hemolytic anemia, leukopenia, and insurance.
Predictors of LLDAS-50

Discussion
LLDAS-50 leads to less organ damage and mortality. 7, 14 Understanding the predictive factors for ability or inability to achieve LLDAS-50 would lead to better clinical trial design and better clinical management of SLE patients. The current study was conducted in one of the largest SLE cohorts, and with a balanced representation of Caucasian and African American ethnicities. We analyzed 2228 patients with a mean of 8.9 years follow-up. To our knowledge, this is the first study to define predictors of LLDAS-50. We took into account individual SLEDAI parameters and not just total SLEDAI, to determine clinical parameters that were associated with or prevented LLDAS-50.
First, over half of SLE patients in our cohort did achieve LLDAS-50. Franklyn et al. found 38.2% of their Caucasian and Asian patients spent !50% of their 3.9 years follow-up in LLDAS. 5 Sharma et al. reported that 33.5% of their Caucasian patients were in LLDAS over 50% of the 125 months of follow-up. 14 The lower proportion of patients with LLDAS-50 in their studies may be due to the longer disease duration in our cohort, as SLE disease activity tends to decrease over time. 22 Tsang-A-Sjoe et al. found 64.5% of their patients (68% Caucasian) achieved LLDAS at 50% of their yearly visits during five years of follow-up. 8 However, their study was based on proportions of yearly visits, not overall time of follow-up.
Second, one of the most important results, not previously studied, is that, compared with other ethnicities, African Americans were significantly less likely to achieve LLDAS-50. Thirty-seven per cent of African American patients versus 64% Caucasian were able to achieve LLDAS-50. African Americans experience more severe SLE, and have a higher risk of lupus nephritis, discoid lupus, and hematologic, serologic, and immunologic SLE manifestations. [23] [24] [25] [26] [27] [28] [29] [30] [31] Even after adjustment for education, insurance, and clinical, serological, and treatment variables, African American ethnicity remained negatively associated with LLDAS-50. Our findings further emphasize the importance of inclusion of African Americans in clinical trials.
Third, a higher percentage of time taking HCQ was an independent modifiable predictor of LLDAS-50. This is a striking finding of this study, since it was the only modifiable predictor even after adjustment for demographics, disease characteristics, and other therapeutics. HCQ has been recommended for all SLE patients irrespective of disease activity, unless contraindicated. 32 It has been shown to improve survival, [33] [34] [35] decrease frequency of lupus flares, 36 and reduce risk of damage accrual. 37 Yet poor adherence to treatment, 38 misdiagnosis of HCQ-related retinopathy, and under dosing due to concern of retinopathy are not uncommon. Adherence in both clinical practice and in randomized clinical trials is essential. Fourth, immunosuppressant drug use was inversely associated with LLDAS-50. Immunosuppressant drug use was also found to be a negative predictor of two consecutive years in LLDAS. 6 Immunosuppressant drugs are recommended to SLE patients with frequent flares, who are unable to be tapered off corticosteroids due to persistent disease activity, frequent flares, or severe organ involvement, 32 which means their use identifies a subset with more severe SLE. The fact that immunosuppressant drug use was a predictor of lack of LLDAS-50 is due to reverse causality: disease activity influences treatment decisions and vice versa. In this context, it would be more reasonable to accentuate other predictors found after adjustment for treatment rather than interpreting immunosuppressant drug use as a predictor.
As expected, the majority of SLE-specific manifestations were less frequent in patients with LLDAS-50. However, patients with a history of mucosal ulcer and livedoid rash were more likely to achieve LLDAS-50. The proportion of LLDAS-50 was similar based on history of Raynaud's, photosensitive rash, subacute cutaneous lupus erythematosus, bullous lupus, and panniculitis.
In the final multivariable model, history of serositis, renal activity, arthritis, vasculitis, malar rash, discoid rash, and thrombocytopenia remained negative predictors of LLDAS-50. Two past studies reported predictors of duration in LLDAS. 6, 9 Skin manifestations and arthritis were found to be negative predictors of both two and five consecutive years in LLDAS. 6, 9 Serositis and vasculitis were found to be negative predictors only for two consecutive years in LLDAS. 6 These results are consistent with ours. Hematological manifestations other than thrombocytopenia, majority of skin manifestations, mouth ulcers, myositis, and anti-Sm were not found to be predictors of LLDAS-50 in our study. Low complement, anti-dsDNA, and anti-RNP prevented LLDAS-50 in our study. Importantly, all of them are more common in African American SLE, 26, 27, 29, 30, 39 and associate with lupus nephritis. 39, 40 Low C3 was an independent predictor of flares at week 52 in the post hoc analysis of belimumab trials, 41 and has been associated with poor survival 42 and incident proteinuria. 43 In contrast with anti-dsDNA, 44 the relationship between disease activity and anti-extractable nuclear antigen antibodies is still controversial. 45 Anti-RNP associates with Raynaud's, leukopenia, and skin manifestations. 46 However, anti-RNP as a negative predictor of LLDAS-50 persisted even after adjustment for anti-RNP associates, suggesting further connection between anti-RNP and prognosis.
Additional findings of this study are of interest. Longer disease duration and older age at diagnosis were associated with LLDAS-50. These results are in agreement with other studies. It is well established that SLE disease activity decreases over time. 22 Patients who were in LLDAS !50% of the observed time were found to be older at diagnosis. 5, 8 Younger age at diagnosis was found to be negatively associated with LLDAS attainment in another study. 47 There are several limitations, including the single center and single rheumatologist in this study. Our cohort consists of mainly patients of Caucasian and African American ethnicity, which did not allow us to investigate Asian American and Hispanic American lupus. We could not include prednisone dose in the analysis as it is a part of the LLDAS definition. 5 In conclusion, in this large cohort, only 52.5% achieved LLDAS-50. This proportion was even less Other covariates that were not significantly predictive of being in Lupus Low Disease Activity state over 50% of the time but included in the selection process were anti-Sm, photosensitive rash, mouth ulcers, alopecia, leg ulcers, livedo, myositis, Coombs, leukopenia, and hemolytic anemia. CI: confidence interval; SLE: systemic lupus erythematosus.
in African Americans. A higher percentage of time taking HCQ was a modifiable predictor of LLDAS-50. Low complement, anti-dsDNA, and anti-RNP were negative predictors. Our findings further emphasize the importance of inclusion of African Americans in clinical trials and HCQ adherence in both clinical practice and clinical trials.
